Citadel Advisors’s EnteroMedics Inc. ETRM Stock Holding History

Citadel Advisors’s Portfolio ETRM Stock Details ETRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-16,421	Closed	-$29K	–	8899
2017 Q3	$29K	Buy	+16,421	New	+$48.4K	﹤0.01%	7301
2017 Q2	–	Sell	-11,119	Closed	-$64K	–	8690
2017 Q1	$64K	Buy	+11,119	New	+$82.2K	﹤0.01%	6988
2015 Q3	–	Sell	-26	Closed	-$17K	–	9759
2015 Q2	$17K	Sell	26 -25	-49%	-$28.8K	﹤0.01%	8255
2015 Q1	$49K	Buy	+51	New	+$61.5K	﹤0.01%	7406
2014 Q4	–	Sell	-5	Closed	-$7K	–	9152
2014 Q3	$7K	Sell	5 -2	-29%	-$2.93K	﹤0.01%	7868
2014 Q2	$11K	Sell	7 -115	-94%	-$215K	﹤0.01%	7571
2014 Q1	$232K	Buy	+122	New	+$289K	﹤0.01%	5359
2013 Q4	–	Sell	-17	Closed	-$23K	–	7536
2013 Q3	$23K	Buy	+17	New	+$19.8K	﹤0.01%	6158

Other funds holding ETRM

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Citadel Advisors's ETRM Position: Q4 2017 in Review

Citadel Advisors sold out of EnteroMedics Inc. (ETRM) in Q4 2017, closing a stake of 16,421 shares — an estimated $29K sold.

Citadel Advisors first reported a position in ETRM in Q3 2013 and held it in 8 quarters. The position peaked at $232K in Q1 2014. 1 fund tracked by Wall St. Rank holds ETRM as of Q4 2017.

Citadel Advisors reported no remaining EnteroMedics Inc. position as of Q4 2017 after selling out during the quarter.
Citadel Advisors sold 16,421 EnteroMedics Inc. shares in Q4 2017, an estimated $29K.
Citadel Advisors first reported a position in EnteroMedics Inc. in Q3 2013 and held it in 8 quarters.
Citadel Advisors's EnteroMedics Inc. position peaked at $232K in Q1 2014.
1 fund tracked by Wall St. Rank held EnteroMedics Inc. as of Q4 2017.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.